Clinical Trial Detail

NCT ID NCT01787500
Title Vemurafenib, Cetuximab, and Irinotecan in Advanced Solid Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors M.D. Anderson Cancer Center
Indications

Advanced Solid Tumor

Therapies

Cetuximab + Irinotecan + Vemurafenib

Age Groups: adult

Additional content available in CKB BOOST